BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.3600
-0.0199 (-5.24%)
Aug 8, 2025, 12:43 PM - Market open
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Ligand Pharmaceuticals stock has a target of 1.00, which predicts a 177.78% increase from the current stock price of 0.36.
Price Target: $1.00 (+177.78%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 31, 2025.
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $5 → $1 | Buy | Maintains | $5 → $1 | +177.78% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 13, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +1,288.89% | Sep 16, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $12 → $5 | Buy | Maintains | $12 → $5 | +1,288.89% | May 23, 2024 |
Financial Forecast
Revenue This Year
n/a
from 11.00M
Revenue Next Year
n/a
EPS This Year
-1.31
from -1.44
EPS Next Year
-1.25
from -1.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.88 | -0.61 | -1.14 | ||
| Avg | -1.31 | -1.25 | -1.11 | ||
| Low | -1.64 | -1.54 | -1.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.